Table of Contents Table of Contents
Previous Page  524 / 812 Next Page
Information
Show Menu
Previous Page 524 / 812 Next Page
Page Background

S520

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

According to the DSM5, Somatic Symptom Disorder (SSD) is char-

acterized by somatic symptoms that are either very distressing

or result in significant disruption of functioning. These criteria

are significantly different compared with previous editions of

DSM. For example, the DSM-IV diagnosis of somatization disor-

der required a specific number of complaints from among four

symptom groups, however the SSD criteria no longer have such

a requirement. Nevertheless somatic symptoms must be signif-

icantly distressing or disruptive to daily life. Very few studies

have focussed on the influence of suffering anhedonia on the per-

ception of somatic symptoms and how this impact on Health

Related Quality of Life (HRQoL), particularly physical function-

ing. We studied the relative impact of somatic symptoms on

the social and physical functioning in depressed patients. More-

over we have explored the influence of anhedonia as measured

by the Snaith-Hamilton Anhedonia Pleasure Scale (SHAPS). We

analysed the correlations between the scores of the 8 dimen-

sions of the SF-36, the SSI-26 and the SHAPS questionnaires.

The results show a significant correlation between SSI-26 score

and physical functioning (

r

= –0.565;

P

< 0.001), role physical

(

r

= –0.551;

P

< 0.001), bodily pain (

r

= –0.659;

P

< 0.001), general

health (

r

= –0.534;

P

< 0.001), vitality (

r

= –0.481;

P

= 0.001), social

functioning (

r

= –0.302;

P

= 0.044) and mental health (

r

= –0.461;

P

= 0.001). Additionally, SHAPS score correlates with vitality

(

r

= –0.371;

P

= 0.012), social functioning (

r

= –0.574;

P

< 0.001) and

mental health (

r

= –0.445;

P

= 0.002). The results demonstrated that

both somatic symptoms and level of anhedonia negatively corre-

late with HRQoL, suggesting a potential relationship between level

of anhedonia and some somatic symptoms. This could impact on

the diagnosis and treatment of depressed patients with somatic

symptoms and anhedonia.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1518

EV534

First evidence for glial pathology in

late life minor depression: S100B is

increased in males with minor

depression

M. Polyakova

1 ,

, C. Sander

2

, K. Arelin

1

, L. Lampe

1

, T. Luck

3

,

J. Kratzsch

4

, K.T. Hoffman

5

, S. Riedel-Heller

3

, A. Villringer

1

,

P. Schoenknecht

2

, M. Schroeter

6

1

Max Planck Institute for Human Cognitive and Brain Sciences,

Neurology, Leipzig, Germany

2

University of Leipzig, University clinics for psychiatry and

psychotherapy, Leipzig, Germany

3

University of Leipzig, Institute of Social Medicine-Occupational

Health and Public Health, Leipzig, Germany

4

University of Leipzig, Institute of Laboratory Medicine- Clinical

Chemistry and Molecular Diagnostics, Leipzig, Germany

5

University of Leipzig, Department of Neuroradiology, Leipzig,

Germany

6

Max Planck Institute for Human Cognitive and Brain Sciences, Day

clinic of cognitive neurology, Leipzig, Germany

Corresponding author.

Minor depression is diagnosed when a patient suffers from two to

four depressive symptoms for at least two weeks. Though minor

depression is a widespread phenomenon, its pathophysiology

has hardly been studied. To get a first insight into the patho-

physiological mechanisms underlying this disorder we assessed

serum levels of biomarkers for plasticity, glial and neuronal

function: brain-derived neurotrophic factor (BDNF), S100B and

neuron specific enolase (NSE). Twenty-seven subjects with minor

depressive episode and 82 healthy subjects over 60 years of

age were selected from the database of the Leipzig population-

based study of civilization diseases (LIFE). Serum levels of BDNF,

S100B and NSE were compared between groups, and corre-

lated with age, body-mass index, and degree of white matter

hyperintensities (score on Fazekas scale). S100B was significantly

increased inmales withminor depression in comparison to healthy

males, whereas other biomarkers did not differ between groups

(

P

= 0.10–0.66). NSE correlated with Fazekas score in patients with

minor depression (

r

s

= 0.436,

P

= 0.048) and in the whole sam-

ple (

r

s

= 0.252,

P

= 0.019). S100B correlated with body mass index

(

r

s

= 0.246,

P

= 0.031) and with age in healthy subjects (

r

s

= 0.345,

P

= 0.002). Increased S100B in males with minor depression, with-

out alterations in BDNF and NSE, supports the glial hypothesis

of depression. Correlation between white matter hyperintensi-

ties and NSE underscores the vascular hypothesis of late life

depression.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1519

EV535

Prevalence of depressive disorders in

andalusia: Results from the PISMA-ep

study

A. Porras Segovia

1 ,

, L. Aguado Bailón

1

, B. Gutiérrez Martínez

2

,

J. Cervilla Ballesteros

1 , 2

1

University Hospital San Cecilio, Mental Health Services, Granada,

Spain

2

University of Granada, Psychiatry Department, Granada, Spain

Corresponding author.

Introduction

Depressive disorders are the most prevalent mental

diseases and they cause a major impact in our society.

Objectives

The objective of this study is to establish the preva-

lence of depressive disorders in Andalusia.

Aims

The aim is to provide useful information regarding this

prevalent and disabling condition, in order to contribute to its pre-

vention and treatment.

Methods

Our results proceed from the PISMA-ep study, under-

took in Andalusia. In this cross-sectional community based study,

4507 participants between 18 and 75 years of agewere interviewed

by fully trained professionals. The main diagnostic tool was the

Spanish version of the MINI Neuropsychiatric International Inter-

view.

Results

Our sample consists of 4507 participants. 50.9% of them

were females. Mean age was 42.8 years. The estimated one-month

prevalence of any mood disorder was 7.9% (7.1–8.6). The estimated

one-month prevalence of major depression was 6, 4% (5.6–7.1).

The prevalence of the other measured depressive disorders were as

follows: Recurrent depressive episode: 3.7% (3.2–4.3), Melancholic

depression: 3% (2.5–3.5), Severe depressive episode with psychotic

symptoms: 1.4% (1.1–1.8).

Conclusions

The PISMA-ep is the first large mental health epi-

demiological study ever developed in the largest region of Spain.

The results obtained in this region show a higher prevalence of

depressive disorders in Andalusia, when comparedwith prior stud-

ies that used a nationally representative sample (i.e. the ESEMeD

study). The reasons for this higher prevalence are yet to be explored.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1520

EV536

Aspects of quality of life in depression

M.G. Puiu

1 ,

, M.C. Manea

2

, I.A. Andrei

1

,

A.M. Cristache

3

, A.A. Frunza

1

, M.C. Boer

4

, B.E. Patrichi

1

,

M.E. Parfene Banu

3

, M. Manea

1

1

“Carol Davila” University of Medicine and Pharmacy, Psychiatry

and Psychology, Bucharest, Romania